MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Becton Dickinson and Co

Geschlossen

BrancheGesundheitswesen

221.9 -2.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

220.16

Max

226.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

-118M

303M

Verkäufe

-272M

5.2B

KGV

Branchendurchschnitt

38.627

63.778

EPS

3.43

Dividendenrendite

1.74

Gewinnspanne

5.863

Angestellte

70,000

EBITDA

-1.3B

453M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+20.96% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.74%

2.39%

Nächstes Ergebnis

1. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-6.1B

66B

Vorheriger Eröffnungskurs

223.95

Vorheriger Schlusskurs

221.9

Nachrichtenstimmung

By Acuity

31%

69%

84 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Becton Dickinson and Co Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Feb. 2025, 22:09 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7. Nov. 2024, 12:59 UTC

Ergebnisse

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7. Nov. 2024, 12:56 UTC

Ergebnisse

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1. Aug. 2024, 11:08 UTC

Ergebnisse

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3. Juni 2024, 11:18 UTC

Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

5. Feb. 2025, 21:56 UTC

Ergebnisse

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5. Feb. 2025, 21:54 UTC

Ergebnisse

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5. Feb. 2025, 21:54 UTC

Ergebnisse

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5. Feb. 2025, 21:53 UTC

Ergebnisse

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q Rev $5.2B >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q Net $303M >BDX

5. Feb. 2025, 21:30 UTC

Ergebnisse

Becton Dickinson 1Q EPS $1.04 >BDX

7. Nov. 2024, 11:36 UTC

Ergebnisse

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7. Nov. 2024, 11:35 UTC

Ergebnisse

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q EPS $1.45 >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q Rev $5.4B >BDX

7. Nov. 2024, 11:30 UTC

Ergebnisse

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

1. Aug. 2024, 10:37 UTC

Ergebnisse

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1. Aug. 2024, 10:35 UTC

Ergebnisse

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1. Aug. 2024, 10:35 UTC

Ergebnisse

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q EPS $1.68 >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q Net $487M >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1. Aug. 2024, 10:30 UTC

Ergebnisse

Becton Dickinson 3Q Rev $5B >BDX

4. Juni 2024, 17:26 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3. Juni 2024, 15:30 UTC

Heiße Aktien

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3. Juni 2024, 13:26 UTC

Akquisitionen, Fusionen, Übernahmen

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3. Juni 2024, 12:25 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Peer-Vergleich

Kursveränderung

Becton Dickinson and Co Prognose

Kursziel

By TipRanks

20.96% Vorteil

12-Monats-Prognose

Durchschnitt 273.88 USD  20.96%

Hoch 280 USD

Tief 260 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Becton Dickinson and Co – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

225.12 / 227.935Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

84 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.